Effects of the CΥP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 3, 1999, Pages 291-294

  Mihara, Kazuo ^a,b,c   Suzuki, Akihito ^a,b,c   Kondo, Tsuyoshi ^a,b,c   Yasui, Norio ^a,b,c   Furukori, Hanako ^a,b,c   Nagashima, Udai ^a,b,c   Otani, Koichi ^a,b,c   Kaneko, Sunao ^a,b,c   Inoue, Yoshimasa ^a,b,c  

^a HIROSAKI UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c Yoshitomi Pharmaceutical Industries Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; DEBRISOQUINE 4 HYDROXYLASE; FLUNITRAZEPAM; HALOPERIDOL; REDUCED HALOPERIDOL; CYTOCHROME P450 2D6; NEUROLEPTIC AGENT;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA; STEADY STATE; ASIAN; BLOOD; DRUG ADMINISTRATION; ENZYMOLOGY; GENETICS; JAPAN;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HALOPERIDOL; HUMANS; JAPAN; MALE; SCHIZOPHRENIA;

EID: 0032588999     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70108-6     Document Type: Article

References (22)

1. 1. Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: clinical implications and unanswered questions. J Clin Psychopharmacol 1994;14:159-62.
2. 2. van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992;149:500-5.
3. 3. LLerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14:92-7.
4. 4. LLerena A, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992;14:261-4.
5. 5. Bertilsson L, Dahl ML. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996;5:200-23.
6. 6. Potkin SG, Shen Y, Pardes H, Phelps BH, Zhou D, Shu L, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 1984; 12:167-72.
7. 7. Lin KM, Poland RE, Lau JK, Rubin RT. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988;8:195-201.
8. 8. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
9. 9. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idre JR, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
10. 10. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
11. 11. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjöqvist F, et al. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995;5:159-64.
12. 12. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996;6:441-7.
13. 13. Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997;7:415-8.
14. 14. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
15. 15. Jann MW, Lam YWF, Chang WH. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Psychopharmacology 1990;101:107-11.
16. 16. Linnoila M, Viukari M, Vaisanen K, Auvinen J. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 1980;137:819-21.
17. 17. Hikida K, Inoue Y, Miyazaki T, Kojima N, Ohkura Y. Determination of bromperidol in serum by automated column-switching high performance liquid chromatography. J Chromatogr 1989;495:227-34 .
18. 18. Yasui N, Kondo T, Otani K, Furukori H, Mihara K, Suzuki A, et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol [in press].
19. 19. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340-3.
20. 20. Bowen WD, Moses EL, Tolentino PJ, Walker JM. Metabolites of haloperidol display preferential activity at σ receptors compared to dopamine D-2 receptors. Eur J Pharmacol 1990;177:111-18.
21. 21. Lane HY, Lin HN, Hu OYP, Chen CC, Jan MW, Chang WH. Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:299-311.
22. 22. Wood AJJ, Zhou H. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991;20:350-73.